There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cassava Sciences (SAVA – Research Report) and Keros Therapeutics (KROS – Research Report) with bullish sentiments.
Cassava Sciences (SAVA)
In a report released today, Vernon Bernardino from H.C. Wainwright reiterated a Buy rating on Cassava Sciences, with a price target of $124.00. The company’s shares closed last Friday at $26.50.
According to TipRanks.com, Bernardino is a 5-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cassava Sciences with a $84.00 average price target, representing a 229.4% upside. In a report issued on February 28, JonesTrading also maintained a Buy rating on the stock with a $100.00 price target.
See the top stocks recommended by analysts >>
Keros Therapeutics (KROS)
H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Keros Therapeutics today and set a price target of $100.00. The company’s shares closed last Friday at $59.32.
According to TipRanks.com, Fein has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Keros Therapeutics with a $96.25 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SAVA:
- Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
- Cassava Sciences announces 2023 scientific goals
- Cassava Sciences reports Q4 EPS (47c), consensus (56c)
- Cassava Sciences provides enrollment update for Phase 3 studies of simufilam
- Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
